Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 16, 2004
- Impact of NHI Price Revision in April Should Be Greater than 4.2% for Some Companies: Mr Yashiro
February 16, 2004
- JPA Warns Against Over-promotion of Self-medication for Economic Reasons
February 16, 2004
- Pfizer Aiming to Make Norvasc Top Japan Drug
February 16, 2004
- EPS, Soiken Form Alliance in Clinical Development of Specified Health Food
February 16, 2004
- NBI Focuses on Neurology, Immunology, CV, Cancer
February 16, 2004
- OTC NEWS IN BRIEF
February 16, 2004
- BUSINESS NEWS IN BRIEF
February 16, 2004
- 1st 3 Qtrs Business Results
February 16, 2004
- WEBSITE NEWS
February 16, 2004
- Over 50% of Patients Think Bungyo Should Be Promoted: Survey
February 16, 2004
- 1st 3 Qtrs Business Results -1-
February 16, 2004
- DIAGNOSTIC NEWS IN BRIEF
February 16, 2004
- 1st 3 Qtrs Business Results -2-
February 16, 2004
- MEDICAL DEVICE NEWS IN BRIEF
February 16, 2004
- New Drug Organization to Start with 9 Departments Responsible for Application Review
February 16, 2004
- WORLD NEWS IN BRIEF
February 16, 2004
- Chuikyo Talks Break Down on Expanding DPC System to Private Hospitals
February 16, 2004
- AnGes MG, Gene Design to Codevelop 3rd-Generation Decoy Products
February 16, 2004
- Caution Urged Again over Long-term Use of Estrogen: Safety Info No. 197
February 9, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…